This study describes new data on case details, history and clinical course of AM that is of preventive, diagnostic and therapeutic value. However, the true impact of the findings of this study on the development of or severity of AM should be tested with case-control studies.

This study refines the list of risk factors for AM. Clinical signs valuable for diagnosis and prognosis have been identified, enabling clinicians to improve management of AM cases.

Differences were encountered during the described outbreak of atypical myopathy in October 2009 compared with previous outbreaks reported. Equine practitioners should be aware that previous epidemiological studies have shown that after a high prevalence in the autumn, new cases are likely to occur in the following spring.

To date, vaccination is one of the most efficient methods of prevention against equine infectious diseases. The vaccinology session, which was organised during the annual meeting of the French Equine Veterinarians Association (AVEF) at Reims (France) in 2016, aimed to approach three subjects of importance for the equine industry. Vaccination against three major equine diseases were used as examples: equine influenza (equine influenza virus), rhinopneumonitis (equine herpes virus 1/4), and tetanus (Clostridium tetani neuro-toxin). (1) Emergency vaccination: while it has been very successful to reduce the impact of equine influenza epizooties and it is also recommended for tetanus in case of surgery and accident, the benefit of emergency vaccination against equine herpes virus 1/4 remains arguable; (2) Compatibility of equine vaccines from different brands: despite being a frequent concerns for equine veterinarians, little information is available about the compatibility of equine vaccines from different commercial origins. The consequence of mixing different equine vaccines targeting the same disease is believed to be limited but scientific evidences are sparse; and, (3) Laps vaccination and vaccine shortage: they could have serious consequences in terms of protection and their impact should be evaluated on a case by case basis, taking into account the risk of contact with the pathogen and the effect on herd immunity.

No abstract

Le réseau d’épidémiosurveillance en pathologie équine (RESPE) est le premier réseau européen de ce type, fondé sur un groupe de vétérinaires sentinelles. Il a un triple objectif : assurer la veille sanitaire de certaines affections ou syndromes, développer un réseau de compétences vétérinaires permettant une collecte rapide d’informations épidémiologiques, et gérer les crises sanitaires hors maladies réglementées, grâce à un système d’alerte et à la constitution d’une cellule de crise. Le bilan du sous-réseau «Syndrome respiratoire aigu» (SRA) démontre l’intérêt et la pertinence du RESPE. Si les résultats ne constituent pas un bilan exhaustif des syndromes respiratoires aigus chez les équidés en France, ils permettent d’évaluer globalement, pour ce syndrome, l’incidence des virus de la grippe, de la rhinopneumonie et de l’artérite virale. L’isolement des souches et leur caractérisation génomique permettent de s’assurer de l’adéquation entre les souches circulantes et les souches vaccinales et de mieux comprendre l’origine des différents foyers. Enfin grâce à la réactivité des vétérinaires sentinelles et des laboratoires impliqués dans ce réseau, il permet la détection des maladies émergentes ou ré-émergentes : l’épisode d’artérite virale lors de l’été 2007 a démontré son efficacité.

Background: Equine herpesvirus type-1 (EHV-1) is an important threat to the equine industry, as illustrated by the ongoing outbreak of neurological disease that was initially reported during a large equestrian event in Valencia, Spain in 2021. Horses returning from this event to their training yards have contributed to the spread of the virus to nine other European countries and to Qatar.Objectives: To design a "tracking" marker in order to specifically follow the dissemination of the Valencia strain, in EHV-1 infected horses with no known epidemiological link with the Valencia outbreak.

Background: Equine herpesvirus type 1 (EHV-1) induces respiratory infection, abortion, and neurologic disease with significant impact.Objectives: Deletion of the virulence factor-encoding open reading frame 2 from the neuropathogenic EHV-1 strain Ab4 yielded a new vaccine candidate, Ab4ΔORF2, which was analysed for safety and efficacy in vivo.